Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$6.92
-0.02-0.29%
At close: -
$6.94
0.020.29%
After Hours: 8:10 AM EDT
Comments
Loading...
Atara Biotherapeutics Analyst Ratings and Price Targets | NASDAQ:ATRA | Benzinga
Atara Biotherapeutics Inc has a consensus price target of $15.15 based on the ratings of 13 analysts. The high is $28 issued by HC Wainwright & Co. on September 26, 2023. The low is $1.4 issued by Citigroup on August 21, 2023. The 3 most-recent analyst ratings were released by Canaccord Genuity, Canaccord Genuity, and Rodman & Renshaw on March 11, 2025, January 17, 2025, and December 20, 2024, respectively. With an average price target of $19.67 between Canaccord Genuity, Canaccord Genuity, and Rodman & Renshaw, there's an implied 183.38% upside for Atara Biotherapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
Rodman & Renshaw
Mizuho
Goldman Sachs
Stifel
1calculated from analyst ratings
Analyst Ratings for Atara Biotherapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/11/2025 | Buy Now | 144.96% | Canaccord Genuity | John Newman45% | $17 → $17 | Maintains | Buy | Get Alert |
| 01/28/2025 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | — | Reiterates | Neutral → Neutral | Get Alert |
| 01/22/2025 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | — | Reiterates | Neutral → Neutral | Get Alert |
| 01/17/2025 | Buy Now | 144.96% | Canaccord Genuity | John Newman45% | $21 → $17 | Maintains | Buy | Get Alert |
| 12/20/2024 | Buy Now | 260.23% | Rodman & Renshaw | Tony Butler43% | → $25 | Initiates | → Buy | Get Alert |
| 11/13/2024 | Buy Now | 202.59% | Canaccord Genuity | John Newman45% | $13 → $21 | Maintains | Buy | Get Alert |
| 08/21/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | — | Reiterates | → Neutral | Get Alert |
| 08/16/2024 | Buy Now | 159.37% | Mizuho | Salim Syed44% | $25 → $18 | Upgrade | Neutral → Outperform | Get Alert |
| 08/13/2024 | Buy Now | 87.32% | Canaccord Genuity | John Newman45% | $13 → $13 | Maintains | Buy | Get Alert |
| 07/17/2024 | Buy Now | 58.5% | Goldman Sachs | Tommie Reerink47% | $12.5 → $11 | Maintains | Sell | Get Alert |
| 05/22/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | — | Reiterates | → Neutral | Get Alert |
| 04/01/2024 | Buy Now | -66.86% | Stifel | Benjamin Burnett46% | $120 → $57.5 | Maintains | Hold | Get Alert |
| 11/10/2023 | Buy Now | -92.8% | Goldman Sachs | Tommie Reerink47% | $75 → $12.5 | Maintains | Sell | Get Alert |
| 11/09/2023 | Buy Now | — | Evercore ISI Group | Michael DiFiore1% | — | Downgrade | Outperform → In-Line | Get Alert |
| 11/09/2023 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | — | Downgrade | Buy → Neutral | Get Alert |
| 11/09/2023 | Buy Now | -85.59% | Mizuho | Salim Syed44% | $775 → $25 | Downgrade | Buy → Neutral | Get Alert |
| 09/26/2023 | Buy Now | 303.46% | HC Wainwright & Co. | — | → $700 | Reiterates | Buy → Buy | Get Alert |
| 08/21/2023 | Buy Now | -79.83% | Citigroup | Yigal Nochomovitz55% | $50 → $35 | Maintains | Sell | Get Alert |
| 08/09/2023 | Buy Now | 260.23% | EF Hutton | Anthony Butler19% | $625 → $625 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2023 | Buy Now | 303.46% | HC Wainwright & Co. | Robert Burns42% | $675 → $700 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 188.18% | Canaccord Genuity | John Newman45% | $1250 → $500 | Maintains | Buy | Get Alert |
| 02/09/2023 | Buy Now | 260.23% | EF Hutton | Anthony Butler19% | $625 → $625 | Reiterates | → Buy | Get Alert |
| 02/09/2023 | Buy Now | 289.05% | HC Wainwright & Co. | Robert Burns42% | $725 → $675 | Maintains | Buy | Get Alert |
| 02/07/2023 | Buy Now | 346.69% | Mizuho | Salim Syed44% | → $775 | Reiterates | → Buy | Get Alert |
| 01/05/2023 | Buy Now | 260.23% | EF Hutton | Tony Butler43% | → $625 | Initiates | → Buy | Get Alert |
| 08/16/2022 | Buy Now | 346.69% | Mizuho | Salim Syed44% | $975 → $775 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | -56.77% | Goldman Sachs | Tommie Reerink47% | $100 → $75 | Maintains | Sell | Get Alert |
| 07/20/2022 | Buy Now | -56.77% | Citigroup | Yigal Nochomovitz55% | → $75 | Downgrade | Neutral → Sell | Get Alert |
| 07/13/2022 | Buy Now | 44.09% | JP Morgan | Anupam Rama60% | → $250 | Downgrade | Overweight → Neutral | Get Alert |
| 07/13/2022 | Buy Now | -27.95% | Stifel | Benjamin Burnett46% | $400 → $125 | Downgrade | Buy → Hold | Get Alert |
| 05/24/2022 | Buy Now | -42.36% | Goldman Sachs | Salveen Richter53% | $125 → $100 | Maintains | Sell | Get Alert |
| 05/23/2022 | Buy Now | 317.87% | HC Wainwright & Co. | Robert Burns42% | $775 → $725 | Maintains | Buy | Get Alert |
| 05/10/2022 | Buy Now | 15.27% | Citigroup | Yigal Nochomovitz55% | $575 → $200 | Downgrade | Buy → Neutral | Get Alert |
| 03/28/2022 | Buy Now | 217% | JP Morgan | Anupam Rama60% | $675 → $550 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Atara Biotherapeutics (ATRA) stock?
The latest price target for Atara Biotherapeutics (NASDAQ:ATRA) was reported by Canaccord Genuity on March 11, 2025. The analyst firm set a price target for $17.00 expecting ATRA to rise to within 12 months (a possible 144.96% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Atara Biotherapeutics (ATRA)?
The latest analyst rating for Atara Biotherapeutics (NASDAQ:ATRA) was provided by Canaccord Genuity, and Atara Biotherapeutics maintained their buy rating.
When was the last upgrade for Atara Biotherapeutics (ATRA)?
The last upgrade for Atara Biotherapeutics Inc happened on August 16, 2024 when Mizuho raised their price target to $18. Mizuho previously had a neutral for Atara Biotherapeutics Inc.
When was the last downgrade for Atara Biotherapeutics (ATRA)?
The last downgrade for Atara Biotherapeutics Inc happened on November 9, 2023 when Evercore ISI Group changed their price target from N/A to N/A for Atara Biotherapeutics Inc.
When is the next analyst rating going to be posted or updated for Atara Biotherapeutics (ATRA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atara Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atara Biotherapeutics was filed on March 11, 2025 so you should expect the next rating to be made available sometime around March 11, 2026.
Is the Analyst Rating Atara Biotherapeutics (ATRA) correct?
While ratings are subjective and will change, the latest Atara Biotherapeutics (ATRA) rating was a maintained with a price target of $17.00 to $17.00. The current price Atara Biotherapeutics (ATRA) is trading at is $6.94, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.